HIFU联用双氟他滨治疗晚期胰腺癌的初步临床研究  

A preliminary clinical study on high intensity focused ultrasound combination with gemcitabine in treating patients with advanced pancreatic carcinoma

作　　者：谢德荣[1] 陈岱佳[1] 滕虹[1] 林显敢[1] 陈积圣[1] 姚波 陈继跃[3] 郑伟华[4] 

机构地区：[1]中山医科大学孙逸仙纪念医院,广州510120 [2]广西柳州铁路中心医院肿瘤科,柳州545007 [3]中国人民解放军421院肿瘤科,广州510310 [4]广东省人民医院肿瘤科,广州510080

出　　处：《岭南现代临床外科》2001年第4期226-228,共3页Lingnan Modern Clinics in Surgery

摘　　要：目的 初步探讨高强度体外聚焦超声(High intensity focused ultrasound,HIFU)热疗联用双氟他滨治疗晚期胰腺癌的疗效及安全性。方法 29例患者符合入组条件。治疗组15例接受HIFU及双氟他滨治疗,对照组14例仅予双氟他滨化疗。两组病例一般临床资料分布均衡。结果 治疗组有效率33.3％,对照组14.3％(P=0.390);临床受益反应率(ClinicalBenefit Respeonse,CBR)80.0％,高于对照组28.6％(P=0.016);中位生存期两组分别为26周和25周(P=0.4962),两组毒副作用轻微,3/4度血小板减少发生率相似(23.7％vs20.8％,P=0.666)。结论 HIFU联用双氟他滨治疗晚期胰腺癌能取得较好的疗效,治疗安全性高,值得临床进一步观察研究。To observe the efficacy and safety of high intensity focused ultrasound(HIFU)combination with gemcitabine in treating patients with advanced pancreatic carcinoma (APC). Methods Twenty nine patients with APC were eligible for this study. Fifteen cases of them enrolled into treatment group who received HIFU combination with gemcitabine chemotherapy,and 14 into control group who received gemcitabine chemotherapy alone.Patient's gen-eral clinical data were comparable in two groups. Results The response rate,Clinical benifit response rate(CBR)and me-dian survival rate were 33.3%,80.0% and 26 weeks for treatment group,14.3% (P = 0.390) ,28.6% (P = 0.016) and 25 weeks ( P=0.496) for control group respectively. Toxicities were mild and grade 3/4 thrombocytopenia was sim-ilar (23.7%vs20.8%,P=0.666) in two arms. Conclusion The preliminary results show that HIFU combination with gemcitabine has a high efficacy and quite safety for APC. It is worthy of further clinical trial.

关 键 词：高强度体外聚焦超声 热疗 双氟他滨 化学治疗 胰腺癌 

分 类 号：R6[医药卫生—外科学]